Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

Blood (2024) 143 (2): 178–182.

https://doi.org/10.1182/blood.2023022345

Published: 2024

Includes: Supplemental data

Journal Articles

Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib

Blood (2022) 140 (Supplement 1): 9721–9723.

https://doi.org/10.1182/blood-2022-162417

Published: 2022

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Blood (2022) 140 (Supplement 1): 9717–9720.

https://doi.org/10.1182/blood-2022-167122

Published: 2022

Journal Articles

Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Blood (2022) 140 (Supplement 1): 1781–1783.

https://doi.org/10.1182/blood-2022-157273

Published: 2022

Journal Articles

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood (2022) 139 (19): 2931–2941.

https://doi.org/10.1182/blood.2021012743

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Blood (2021) 138 (Supplement 1): 139.

https://doi.org/10.1182/blood-2021-148682

Published: 2021

Journal Articles

Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study

Chandan Saha, Carolyn Mead-Harvey, Adam J. Mead, Rebecca H. Boucher, Sonia Fox, Isaak Ailts, Christina Yap, Aimee E Jackson, Joanne Ewing, Jason Coppell, Steve Knapper, Mark W. Drummond, Anna L Godfrey, Amylou C. Dueck, Ruben A. Mesa, Robyn Scherber, Mary Frances McMullin, Holly L. Geyer, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 1507.

https://doi.org/10.1182/blood-2021-151568

Published: 2021

Journal Articles

Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera

Isaak Ailts, Carolyn Mead-Harvey, Adam J. Mead, Sonia Fox, Rebecca H. Boucher, Christina Yap, Chandan Saha, Robyn Scherber, Aimee Jackson, Joanne Ewing, Jason Coppell, Steve Knapper, Mark W. Drummond, Anna L Godfrey, Amylou C. Dueck, Mary Frances McMullin, Ruben A. Mesa, Claire N. Harrison, Holly L. Geyer

Blood (2021) 138 (Supplement 1): 3644.

https://doi.org/10.1182/blood-2021-147637

Published: 2021

Journal Articles

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

Claire Harrison, DM, FRCP, FRCPath, Joanna Baxter, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Thomas McKerrell, MD PhD, Aimee Jackson, BSc, MSc, Rachel S Fletcher, PhD, Adam J. Mead, MD PhD, Steve Knapper, BMBCh, MRCP, FRCPath, DM, Joanne Ewing, MD PhD, Nauman M Butt, MD, Manish Jain, MBBS, MRCP, FRCpath, Sebastian Francis, MBChB, FRCPath, MD, Fiona J Clark, FRCP, FRCPath, Jason Coppell, MBBS, Mary Frances McMullin, MDFRCP, FRCPath, Frances Wadelin, MB ChB, PhD FRCPath, Srinivasan Narayanan, FRCP, FRCPath, Dragana Milojkovic, Mark W. Drummond, PhD FRCPath, Mallika Sekhar, MBBS, MD, Maike Paramor, James Roberts, BSc, Rachel Glover, BSc, Erica Harris, MSc, Luigi Grassi, PhD, Alba Rodriguez-Meira, PhD, Jason Carroll, PhD FMedSci, José-Ezequiel Martín, PhD, Giuditta Corbizi Fattori, PhD, Zijian Fang, BSc, Anna L Godfrey, BMBCh, PhD, Simón Méndez-Ferrer, PhD

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-134764

Published: 2020

Journal Articles

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Blood (2019) 134 (Supplement_1): 2935.

https://doi.org/10.1182/blood-2019-129825

Published: 2019

Journal Articles

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Blood (2019) 134 (Supplement_1): 2943.

https://doi.org/10.1182/blood-2019-124865

Published: 2019

Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2945.

https://doi.org/10.1182/blood-2019-123836

Published: 2019

Journal Articles

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

Jenny Byrne, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Adam J. Mead, MD PhD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Gavin Campbell, FRCP,FRCPath, Ian Amott, Andrew Goringe, Earnest Heartin, Evangelia Dimitriadou, MD, Ian Pamphlett, Siamak Arami, MD MRCP, FRCPath, Pratap Neelakantan, Rebecca Frewin, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Hugues De Lavallade, Nicholas C.P. Cross, Michael Thompson

Blood (2019) 134 (Supplement_1): 3434.

https://doi.org/10.1182/blood-2019-122893

Published: 2019

Journal Articles

A Retrospective Real-World Study of the Current Treatment Pathways for Myelofibrosis in the UK (The REALISM UK Study)

Adam J. Mead, MD PhD, Tim Somervaille, Professor, MD, Nauman M Butt, MD, Waseem Nagi, MD FRCPath, Alastair J Whiteway, MBBS, Suriya Kirkpatrick, MD, Ciro R Rinaldi, MD PhD, Catherine Roughley, MD, Sam Ackroyd, MD, Joanne Ewing, PhDBMBS BSc FRPATH, Pratap Neelakantan, MD FRCPath, Mamta Garg, MD FRCP, FRCPath, Claire N Harrison, Professor, David Tucker, MD, Rozinder Bains, Gavin Chiu, MBBS, MRCGP, MFPM, DPM, BSc, Joe Hickey, PhD

Blood (2019) 134 (Supplement_1): 1671.

https://doi.org/10.1182/blood-2019-124686

Published: 2019

Journal Articles

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Blood (2018) 132 (Supplement 1): 1762.

https://doi.org/10.1182/blood-2018-99-111559

Published: 2018

Journal Articles

Azacitidine Improves Outcome in Patients with MDS and AML with High Risk Cytogenetics - a Single Center Experience

Vidhya Murthy, MRCP,, Nilupulee Kapuge, Charalampos Kartsios, MD, Joanne Ewing, PhD BMBS, BSc, FRPATH,, Evgenia Xenou, Maria Kaparou, Elmoamly Shereef, Emmanouil Nikolousis

Blood (2018) 132 (Supplement 1): 5529.

https://doi.org/10.1182/blood-2018-99-109774

Published: 2018

Journal Articles

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Blood (2018) 132 (Supplement 1): 577.

https://doi.org/10.1182/blood-2018-99-111946

Published: 2018

Journal Articles

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Blood (2018) 132 (Supplement 1): 3032.

https://doi.org/10.1182/blood-2018-99-111929

Published: 2018

Journal Articles

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Allison Scotch, MD MPH, Robyn M. Scherber, MD, Marlene Bruso, MS, Heidi Elizabeth Kosiorek, MS, Amylou C. Dueck, PhD, Holly Geyer, MD, Veena D. S. Fauble, MD, Alessandro M. Vannucchi, Ana Kerguelen Fuentes, Christen Lykkegaard Andersen, PhD, Elisabeth Ejerblad, MD, Gunnar Birgegard, MD PhD, Peter L. Johansson, MD PhD, Bjorn Andreasson, David M Ross, MBBS, PhD FRACP, FRCPA, Federico Sackman, MD PhD, Jean-Loup Demory, MD PhD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Jan J. Michiels, PhD, Deepti Radia, MD, Joanne Ewing, PhD BMBS, BSc, FRPATH,, Frances Wadelin, MD, Robert N. Lown, MBBS, MRCP, MD, Mary Frances McMullin, MB,Bch BAO, MD FRCPath, Wunna Swe, Jonathan O. Cullis, MD, Nigel Sargant, BSc, FRPATH, MRCP,, Paul Moreton, MD MRCP, FRCPath, Catherine Cargo, MB, FRCPath, Mallika Sekhar, MBBS, MD FRCPath, FRCP, Satareh Shekouhi, Ruben A Mesa, MD

Blood (2017) 130 (Supplement 1): 1641.

https://doi.org/10.1182/blood.V130.Suppl_1.1641.1641

Published: 2017

Journal Articles

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

Blood (2017) 130 (17): 1889–1897.

https://doi.org/10.1182/blood-2017-05-785790

Published: 2017

Includes: Supplemental data

NARROW

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study

Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

A Retrospective Real-World Study of the Current Treatment Pathways for Myelofibrosis in the UK (The REALISM UK Study)

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Azacitidine Improves Outcome in Patients with MDS and AML with High Risk Cytogenetics - a Single Center Experience

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only